New hope for tough myeloma: first human trial of JNJ-87562761 begins

NCT ID NCT06604715

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug, JNJ-87562761, in 17 people with multiple myeloma whose cancer returned or didn't respond to prior treatments. The main goals are to find a safe dose and check for side effects. Participants must have measurable disease and have tried certain prior therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Asan Medical Center

Seoul, 05505, South Korea
China Medical University Hospital

Taichung, 404, Taiwan
Clinica Univ. de Navarra

Pamplona, 31008, Spain
Hosp Clinic de Barcelona

Barcelona, 08036, Spain
Hosp Clinico Univ de Salamanca

Salamanca, 37007, Spain
Hosp Univ Fund Jimenez Diaz

Madrid, 28040, Spain
Hosp. Univ. Germans Trias I Pujol

Badalona, 08916, Spain
Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, 833, Taiwan
National Cheng Kung University Hospital

Tainan, 70403, Taiwan
National Taiwan University Hospital

Taipei, 100225, Taiwan
Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
Samsung Medical Center

Seoul, 06351, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
The Catholic University of Korea Seoul St Marys Hospital

Seoul, 137 701, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.